Viking Therapeutics Inc. (NASDAQ: VKTX) reported earnings after the market closed on Apr. 23. The stock is pushing higher as investors attempt to sort out a report that delivered no real news that investors hadn’t heard.
The company, which is still in the pre-revenue stage, reported negative earnings per share of 41 cents. That was below the negative 34 cents per share that analysts had expected and below the negative 27 cents per share it delivered in the same quarter in 2024. The company also reported a slight drawdown in its cash, cash equivalents and short-term investments to $852 million.
